# Evaluation of Performance and Safety of Carbopol 980 NF 0.2%- Based Medical Device in the Management of Patients With Glaucomar or Ocular Hypertension and Concomitant Dry Eye Syndrome on Multiple Long-term Topical Hypotensive Therapy

> **NCT06190028** · NA · TERMINATED · sponsor: **Fidia Farmaceutici s.p.a.** · enrollment: 65 (actual)

## Conditions studied

- Dry Eye Syndrome
- Glaucoma and Concomitant Dry Eye Syndrome
- Ocular Hypertension and Concomitant Dry Eye Syndrome
- Multiple Long-term Topical Hypotensive Therapy

## Interventions

- **DEVICE:** Iridium A Gel

## Key facts

- **NCT ID:** NCT06190028
- **Lead sponsor:** Fidia Farmaceutici s.p.a.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-06-14
- **Primary completion:** 2025-03-10
- **Final completion:** 2025-03-10
- **Target enrollment:** 65 (ACTUAL)
- **Why stopped:** The investigation was prematurely interrupted with 65 patients enrolled due to difficulties in recruiting patients. However the results observed in the interim analysis demonstrate the performance of the investigational device.
- **Last updated:** 2026-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06190028

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06190028, "Evaluation of Performance and Safety of Carbopol 980 NF 0.2%- Based Medical Device in the Management of Patients With Glaucomar or Ocular Hypertension and Concomitant Dry Eye Syndrome on Multiple Long-term Topical Hypotensive Therapy". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06190028. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*